225 related articles for article (PubMed ID: 21159637)
1. Active immunotherapy induces antibody responses that target tumor angiogenesis.
Schoenfeld J; Jinushi M; Nakazaki Y; Wiener D; Park J; Soiffer R; Neuberg D; Mihm M; Hodi FS; Dranoff G
Cancer Res; 2010 Dec; 70(24):10150-60. PubMed ID: 21159637
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
3. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
[TBL] [Abstract][Full Text] [Related]
4. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
Fonseca C; Soiffer R; Ho V; Vanneman M; Jinushi M; Ritz J; Neuberg D; Stone R; DeAngelo D; Dranoff G
Blood; 2009 Feb; 113(8):1681-8. PubMed ID: 19008459
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
6. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
7. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
Hodi FS; Schmollinger JC; Soiffer RJ; Salgia R; Lynch T; Ritz J; Alyea EP; Yang J; Neuberg D; Mihm M; Dranoff G
Proc Natl Acad Sci U S A; 2002 May; 99(10):6919-24. PubMed ID: 11983866
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF-based cancer vaccines.
Dranoff G
Immunol Rev; 2002 Oct; 188():147-54. PubMed ID: 12445288
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
10. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
11. The biologic importance of tumor-infiltrating lymphocytes.
Hodi FS; Dranoff G
J Cutan Pathol; 2010 Apr; 37 Suppl 1(0 1):48-53. PubMed ID: 20482675
[TBL] [Abstract][Full Text] [Related]
12. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
Schmollinger JC; Vonderheide RH; Hoar KM; Maecker B; Schultze JL; Hodi FS; Soiffer RJ; Jung K; Kuroda MJ; Letvin NL; Greenfield EA; Mihm M; Kutok JL; Dranoff G
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3398-403. PubMed ID: 12626761
[TBL] [Abstract][Full Text] [Related]
13. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
14. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
15. PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
[TBL] [Abstract][Full Text] [Related]
16. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas M; Kienast Y; Scheuer W; Bähner M; Kaluza K; Gassner C; Herting F; Brinkmann U; Seeber S; Kavlie A; Welschof M; Ries S; Weidner KM; Regula JT; Klein C
PLoS One; 2013; 8(2):e54923. PubMed ID: 23405099
[TBL] [Abstract][Full Text] [Related]
17. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
Kamstock D; Elmslie R; Thamm D; Dow S
Cancer Immunol Immunother; 2007 Aug; 56(8):1299-309. PubMed ID: 17502972
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF-secreting melanoma vaccines.
Dranoff G
Oncogene; 2003 May; 22(20):3188-92. PubMed ID: 12789295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
